Skip to main content

Advertisement

SpringerLink
Log in

Current research topics in endocrine therapy for breast cancer

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

There are large-scale molecular differences between estrogen receptor (ER)-positive and ER-negative breast cancers. Endocrine therapy has become the most important treatment option for women with ER-positive breast cancer, and approximately 70% of primary breast cancers express ERα. Endocrine therapy has provided meaningful advances in breast cancer treatment and prevention. However, some patients continue to develop recurrence and die of the disease. New insights into ER biology and progress in the understanding of resistance mechanisms are generating tremendous promise for new therapeutic opportunities to target resistance and improve disease outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Article  CAS  Google Scholar 

  2. Baum M, Budzar AU, Cuzick J, et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139

    Article  PubMed  CAS  Google Scholar 

  3. Coombes RC, Hall E, Gibson LJ, et al. (2004) A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081–1092

    Article  PubMed  CAS  Google Scholar 

  4. Thurlimann B, Keshaviah A, Coates AS, et al. (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757

    Article  PubMed  Google Scholar 

  5. Yamashita H, Ando Y, Nishio M, et al. (2006) Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 13:74–83

    Article  PubMed  Google Scholar 

  6. Herynk MH, Fuqua, SA (2004) Estrogen receptor mutations in human disease. Endocr Rev 25:869–898

    Article  PubMed  CAS  Google Scholar 

  7. Giacinti L, Claudio PP, Lopez M, et al. (2006) Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11:1–8

    Article  PubMed  CAS  Google Scholar 

  8. Holst F, Stahl PR, Ruiz C, et al. (2007) Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39:655–660

    Article  PubMed  CAS  Google Scholar 

  9. Albertson DG (2008) Conflicting evidence on the frequency of ESR1 amplification in breast cancer. Nat Genet 40:821–822

    Article  PubMed  CAS  Google Scholar 

  10. Esquela-Kerscher A, Slack, FJ (2006) Oncomirs — microRNAs with a role in cancer. Nat Rev Cancer 6:259–269

    Article  PubMed  CAS  Google Scholar 

  11. Adams BD, Furneaux H, White BA (2007) The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 21:1132–1147

    Article  PubMed  CAS  Google Scholar 

  12. Kondo N, Toyama T, Sugiura H, et al. (2008) miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 68:5004–5008

    Article  PubMed  CAS  Google Scholar 

  13. Osborne CK, Schiff R (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23:1616–1622

    Article  PubMed  CAS  Google Scholar 

  14. Massarweh S, Schiff R (2007) Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res 13:1950–1954

    Article  PubMed  CAS  Google Scholar 

  15. Kurokawa H, Lenferink AE, Simpson JF, et al. (2000) Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60:5887–5894

    PubMed  CAS  Google Scholar 

  16. Ellis MJ, Coop A, Singh B, et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808–3816

    PubMed  CAS  Google Scholar 

  17. Gee JM, Robertson JF, Ellis IO, et al. (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95:247–254

    Article  PubMed  CAS  Google Scholar 

  18. Tokunaga E, Kimura Y, Mashino K, et al. (2006) Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 13:137–144

    Article  PubMed  Google Scholar 

  19. Martin LA, Farmer I, Johnston SR, et al. (2005) Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer 12(Suppl 1):S75–S84

    Article  PubMed  CAS  Google Scholar 

  20. Moy B, Goss PE (2006) Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res 12:4790–4793

    Article  PubMed  CAS  Google Scholar 

  21. Leary AF, Sirohi B, Johnston SR (2007) Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. Breast Cancer Res 9:112

    Article  PubMed  CAS  Google Scholar 

  22. Yamashita H, Nishio M, Kobayashi S, et al. (2005) Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res 7:R753–R764

    Article  PubMed  CAS  Google Scholar 

  23. Yamashita H, Nishio M, Toyama T, et al. (2008) Low phosphorylation of ER{alpha} serine 118 and high phosphorylation of ER{alpha} serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer

  24. Goetz MP, Rae JM, Suman VJ, et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318

    Article  PubMed  CAS  Google Scholar 

  25. Lim HS, Ju Lee H, Seok Lee K, et al. (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25:3837–3845

    Article  PubMed  CAS  Google Scholar 

  26. Schroth W, Antoniadou L, Fritz P, et al. (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187–5193

    Article  PubMed  CAS  Google Scholar 

  27. Punglia RS, Burstein HJ, Winer EP, et al. (2008) Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 100:642–648

    Article  PubMed  CAS  Google Scholar 

  28. Xu Y, Sun Y, Yao L, et al. (2008) Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol

  29. Kiyotani K, Mushiroda T, Sasa M, et al. (2008) Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 99:995–999

    Article  PubMed  CAS  Google Scholar 

  30. Jin Y, Desta Z, Stearns V, et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39

    Article  PubMed  CAS  Google Scholar 

  31. Ma CX, Adjei AA, Salavaggione OE, et al. (2005) Human aromatase: gene resequencing and functional genomics. Cancer Res 65:11071–11082

    Article  PubMed  CAS  Google Scholar 

  32. Ingle JN (2008) Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 112:695–699

    Article  PubMed  CAS  Google Scholar 

  33. Hanash S (2004) Integrated global profiling of cancer. Nat Rev Cancer 4:638–644

    Article  PubMed  CAS  Google Scholar 

  34. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721–728

    Article  PubMed  Google Scholar 

  35. Cardoso F, Van’t Veer L, Rutgers E, et al. (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26:729–735

    Article  PubMed  Google Scholar 

  36. Paik S, Shak S, Tang G, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826

    Article  PubMed  CAS  Google Scholar 

  37. Habel LA, Shak S, Jacobs MK, et al. (2006) A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25

    Article  PubMed  CAS  Google Scholar 

  38. Paik S, Tang G, Shak S, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 24:3726–3734

    Article  PubMed  CAS  Google Scholar 

  39. Sparano JA (2006) TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347–350

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan

    Hiroko Yamashita

Authors
  1. Hiroko Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroko Yamashita.

About this article

Cite this article

Yamashita, H. Current research topics in endocrine therapy for breast cancer. Int J Clin Oncol 13, 380–383 (2008). https://doi.org/10.1007/s10147-008-0818-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-008-0818-7

Key words

Search

Navigation